EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Allogeneic hematopoietic cell transplantation for partial RAG deficiency in children and adults: Excellent outcomes with a reduced-intensity posttransplantation cyclophosphamide–based approach

Dimana Dimitrova, Marita Bosticardo, Ottavia M Delmonte, Heather Kenney, Annie An, Francesca Pala, Gloria Magro, Katherine Myint-Hpu, Esther Kang, Enrico Santangeli, Angelina Angelova, Ivan Vujkovic-Cvijin und 24 weitere

Journal of Allergy and Clinical Immunology · 2026

DOI: 10.1016/j.jaci.2026.01.030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology, 2026. Verfasst von Dimana Dimitrova und 35 weiteren Autor:innen. Beteiligte Einrichtung: Center for Immuno-Oncology, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Md. Ele…. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Graft vs Host Disease, Transplantation Conditioning. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Intramural NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Partial recombinase activating gene deficiency (pRD) leads to combined immunodeficiency with immune dysregulation. It can be cured by allogeneic hematopoietic cell transplantation (HCT), but optimal referral criteria and approaches remain to be defined. OBJECTIVE: Our study evaluated low-toxicity approaches to HCT for pRD. METHODS: Thirteen children and adults with pRD received radiation-free, predominantly reduced-intensity conditioning (pentostatin/cyclophosphamide/busulfan) HCT with posttransplantation cyclophosphamide-based graft-versus-host disease (GVHD) prophylaxis at median (range) age 20 (4-46) years. RESULTS: B cells decreased after HCT, along with clinically relevant autoantibodies. However, baseline elevated anti-type I interferon antibodies, potentially predisposing to severe viral infections, decreased slowly, although neutralizing activity was reduced at last follow-up. Outcomes did not differ by donor carrier status or HLA matching. Bronchiectasis exacerbations incurred rehospitalizations in long-term follow-up of patients who entered HCT with irreversible lung disease. CONCLUSION: Reduced-intensity conditioning HCT with posttransplantation cyclophosphamide-based GVHD prophylaxis is safe and effectively reverses immune dysfunction in patients with pRD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationCyclophosphamideGraft vs Host DiseaseTransplantation ConditioningHomeodomain ProteinsImmunosuppressive AgentsImmunologic Deficiency SyndromesHumansChild, PreschoolChildFemaleAdolescentMaleAdultTransplantation, HomologousMiddle AgedYoung AdultTreatment Outcome

Stichwörter der Autor:innen

combined immunodeficiencyimmune dysregulationpartial RAG deficiencyposttransplantation cyclophosphamidereduced intensity conditioning

Substanzen

CyclophosphamideHomeodomain ProteinsImmunosuppressive AgentsRAG-1 protein

Autor:innen und Institutionen

  • Center for Immuno-Oncology, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Md. Electronic address: Dimana.dimitrova@nih.gov.
  • Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Md.
  • Bioinformatics and Computational Biosciences Branch, NIAID, NIH, Bethesda, Md.
  • F. Widjaja Inflammatory Bowel Disease Institute, Cedars-Sinai Medical Center, Los Angeles, Calif.
  • Research and Technologies Branch, NIAID, NIH, Bethesda, Md.
  • Center for Immuno-Oncology, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Md.

Förderung

  • Intramural NIH HHS
  • National Institutes of Health

Zitieren

APA

Dimitrova, D., Bosticardo, M., Delmonte, O. M., Kenney, H., An, A., Pala, F., Magro, G., Myint-Hpu, K., Kang, E., Santangeli, E., Angelova, A., Vujkovic-Cvijin, I., Schwarz, B., Campos, J., Chai, A., Cusmano, A., Flomerfelt, F. A., Hyder, M. A., Mangusan, R., …, & Kanakry, J. A. (2026). Allogeneic hematopoietic cell transplantation for partial RAG deficiency in children and adults: Excellent outcomes with a reduced-intensity posttransplantation cyclophosphamide–based approach. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2026.01.030

Vancouver

Dimitrova D, Bosticardo M, Delmonte OM, Kenney H, An A, Pala F, et al. Allogeneic hematopoietic cell transplantation for partial RAG deficiency in children and adults: Excellent outcomes with a reduced-intensity posttransplantation cyclophosphamide–based approach. Journal of Allergy and Clinical Immunology. 2026. doi:10.1016/j.jaci.2026.01.030

BibTeX
@article{Dimitrova2026,
  author = {Dimitrova, Dimana and Bosticardo, Marita and Delmonte, Ottavia M and Kenney, Heather and An, Annie and Pala, Francesca and Magro, Gloria and Myint-Hpu, Katherine and Kang, Esther and Santangeli, Enrico and Angelova, Angelina and Vujkovic-Cvijin, Ivan and Schwarz, Benjamin and Campos, Jessenia and Chai, Amy and Cusmano, Alison and Flomerfelt, Francis A and Hyder, Mustafa A and Mangusan, Ralph and Rechache, Kamil and Sabina, Ruby and Telford, William and Kong, Heidi H and Nagao, Keisuke and Agharahimi, Anahita and Bergerson, Jenna R E and Freeman, Alexandra F and Holland, Steven M and Ale, Hanadys and El-Marsafy, Aisha and Pasic, Srdjan and Verbsky, James and Walter, Jolan and Kanakry, Christopher G and Notarangelo, Luigi D and Kanakry, Jennifer A},
  title = {Allogeneic hematopoietic cell transplantation for partial RAG deficiency in children and adults: Excellent outcomes with a reduced-intensity posttransplantation cyclophosphamide–based approach},
  journal = {Journal of Allergy and Clinical Immunology},
  year = {2026},
  doi = {10.1016/j.jaci.2026.01.030}
}
Kostenlos starten →